the evaluation of effectiveness of oral silymarin on memory status of patients with dementia

INTERVENTION: Intervention 1: Silymarin, 140 mg tablets, 3 times a day (trade name, Livergol, goldaru company), for 12 weeks. Intervention 2: Placebo tablets identical to silymarin tablets in shape and color, 3 times a day, for 12 weeks. Placebo tablets are made in pharmacology faculty of kermanshah university of medical sciences. Placebo Placebo tablets identical to silymarin tablets in shape and color, 3 times a day, for 12 weeks. Placebo tablets are made in pharmacology faculty of kermanshah university of medical sciences. Silymarin, 140 mg tablets, 3 times a day (trade name, Livergol, goldaru company), for 12 weeks Treatment ‐ Drugs CONDITION: Alzheimer disease is a primary degenerative cerebral disease of unknown etiology with characteristic neuropathological and neurochemical features. The disorder is usually insidious in onset and develops slowly but steadily over a period of several years. Cases of dementia due, or presumed to be due, to causes other than Alzheimer disease or cerebrovascular disease. Onset may be at any time in life, though rarely in old age. Condition 1: Dementia in Alzheimer disease. Condition 2: Vascular dementia. Condition 3: Dementia in other diseases classified elsewhere. ; Alzheimer disease is a primary degenerative cerebral disease of unknown etiology with characteristic neuropathological and neurochemical features. The disorder is usually insidious in onset and develops slowly but steadily over a period of several years. ; Vascular dementia is the result of infarction of the brain due to vascular disease, including hypertensive cerebrovascular disease. The infarcts are usually small but cumulative in their effect. Onset is usually in later life. ; Cases of dementia due, or presumed to be due, to causes other than Alzheimer disease or cerebrovascular disease. Onset may be at any time in life, though rarely in old age. Vascular dementia is the result of infarction of the brain due to vascular disease, including hypertensive cerebrovascular disease. The infarcts are usually small but cumulative in their effect. Onset is usually in later life. PRIMARY OUTCOME: Memory status of patients. Timepoint: before and 12 weeks after intervention. Method of measurement: mini mental state examination scale. SECONDARY OUTCOME: Drug side effects. Timepoint: 12 weeks after intervention. Method of measurement: history and physical examination. INCLUSION CRITERIA: INCLUSION CRITERIA: 1. definite diagnosis of dementia by an experienced neurologist 2. at least one year has past form the time of the diagnosis exclusion criteria: 1. illiterate persons 2. having epilepsy, cardiovascular diseases, metabolic diseases, respiratory diseases, orthopedic problems and renal failure with serum cratinin level more than 2 3. history of previous stroke 4. acute and severe state of any disease including stroke, pulmonary infection, renal disease, metabolic disturbance or trauma leading to hospitalization during the study 5. using other self care programs that are effective on memory state of patents at the same time of study intervention